Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews

被引:10
作者
Acquaye, Alvina A. [1 ]
Payen, Samuel S. [2 ]
Vera, Elizabeth [1 ]
Williams, Loretta A. [3 ]
Gilbert, Mark R. [1 ]
Weathers, Shiao-Pei [4 ]
Armstrong, Terri S. [1 ]
机构
[1] NIH, Neuioonco Branch, 9030 Old Georgetown Rd,Room 231, Bethesda, MD 20892 USA
[2] Univ Texas Hlth Sci Ctr Nursing Res, Dept Family Hlth Houston, Houston, TX USA
[3] Anderson Canc Ctr, Dept Symptom Res, Houston, TX USA
[4] Anderson Canc Ctr, Dept Neurooncol, Houston, TX USA
关键词
MDASI-BT; Patient outcomes; Brain tumors; Quality of life; Symptom management; Qualitative research; CLINICAL-OUTCOME ASSESSMENT; END-POINTS; BENEFIT; BURDEN; MODULE; TRIAL; SIGNS;
D O I
10.1186/s41687-019-0143-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Identifying symptoms experienced throughout the disease trajectory is pivotal to understanding management of patient symptoms. Patient interviews to solicit input from those who have experienced these symptoms is one method to capture this perspective to validate symptoms included in patient reported outcomes (PRO) measures. Methods A thematic approach was used to identify themes within qualitative interviews. The MD Anderson Symptom Inventory- Brain Tumor (MDASI-BT) was completed by glioma patients. Descriptive statistics was used for analysis of the MDASI-BT. Results Thematic saturation was reached with 23 participants, with a median age of 53 (23-62), on treatment (57%) and diagnosed with a glioblastoma (48%). Patients endorsed 20 out of the 22 MDASI-BT symptoms (symptoms not reported: dry mouth, shortness of breath) during the interviews and with completion of the instrument (seizures and vomiting were not endorsed). Fatigue (55%), seizures (50%), and pain (50%) were common symptoms described by the sample. During treatment, more symptoms were identified with fatigue, hair loss, and nausea more problematic. Aside from itching and swelling (endorsed by 2 patients each), all other symptoms not included in the MDASI-BT instrument were endorsed by only one patient. Conclusions Completion of the MDASI-BT, found patients reported on average 6.8 symptoms with 14% of reported symptoms (mean = 3) rated as moderate to severe. The findings demonstrate how applicable the MDASI-BT is in capturing significant symptoms experienced and how important it is to utilize throughout ones' care to manage symptoms effectively.
引用
收藏
页数:10
相关论文
共 23 条
[1]   Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) [J].
Armstrong, T. S. ;
Mendoza, T. ;
Gring, I. ;
Coco, C. ;
Cohen, M. Z. ;
Eriksen, L. ;
Hsu, Ming-Ann ;
Gilbert, M. R. ;
Cleeland, C. .
JOURNAL OF NEURO-ONCOLOGY, 2006, 80 (01) :27-+
[2]   Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report [J].
Armstrong, Terri S. ;
Bishof, Allison M. ;
Brown, Paul D. ;
Klein, Martin ;
Taphoorn, Martin J. B. ;
Theodore-Oklota, Christina .
NEURO-ONCOLOGY, 2016, 18 :1-12
[3]   The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms [J].
Armstrong, Terri S. ;
Vera-Bolanos, Elizabeth ;
Acquaye, Alvina A. ;
Gilbert, Mark R. ;
Ladha, Harshad ;
Mendoza, Tito .
NEURO-ONCOLOGY, 2016, 18 (02) :252-260
[4]   Patient Reported Endpoints for Measuring Clinical Benefit in (High Grade Glioma) Primary Brain Tumor Patients [J].
Armstrong, Terri S. ;
Gilbert, Mark R. .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (04) :519-528
[5]   Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma [J].
Armstrong, Terri S. ;
Wefel, Jeffrey S. ;
Wang, Meihua ;
Gilbert, Mark R. ;
Won, Minhee ;
Bottomley, Andrew ;
Mendoza, Tito R. ;
Coens, Corneel ;
Werner-Wasik, Maria ;
Brachman, David G. ;
Choucair, Ali K. ;
Mehta, Minesh .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4076-+
[6]   The Impact of Symptom Interference Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) on Prediction of Recurrence in Primary Brain Tumor Patients [J].
Armstrong, Terri S. ;
Vera-Bolanos, Elizabeth ;
Gning, Ibrahima ;
Acquaye, Alvina ;
Gilbert, Mark R. ;
Cleeland, Charles ;
Mendoza, Tito .
CANCER, 2011, 117 (14) :3222-3228
[7]   Content validity of self-report measurement instruments: An illustration from the development of the brain tumor module of the M.D. Anderson Symptom Inventory [J].
Armstrong, TS ;
Cohen, MZ ;
Eriksen, L ;
Cleeland, C .
ONCOLOGY NURSING FORUM, 2005, 32 (03) :669-676
[8]   Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors [J].
Armstrong, TS ;
Cohen, MZ ;
Eriksen, LR ;
Hickey, JV .
JOURNAL OF NURSING SCHOLARSHIP, 2004, 36 (03) :197-206
[9]   Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations [J].
Blakeley, Jaishri O. ;
Coons, Stephen Joel ;
Corboy, John R. ;
Leidy, Nancy Kline ;
Mendoza, Tito R. ;
Wefel, Jeffrey S. .
NEURO-ONCOLOGY, 2016, 18 :13-20
[10]  
Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [DOI 10.1191/1478088706QP063OA, 10.1191/1478088706qp063oa]